Yes – Teva’s generic tadalafil is fully approved and marketed throughout the European Union.
| Country (or region) | Approval body | Date of first marketing authorization | Brand name(s) used |
|---------------------|----------------|---------------------------------------|--------------------|
| EU‑wide (through the EMA) | European Medicines Agency (via national regulators) | July 2014 (first 5 mg tablet) | Tadze (generic) |
| UK | Medicines and Healthcare products Regulatory Agency (MHRA) | March 2016 | Tadze (generic) |
| Spain | Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) | 2014 | Tadze |
| France | Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) | 2014 | Tadze |
| Germany | Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) | 2014 | Tadze |
| Italy | Agenzia Italiana del Farmaco (AIFA) | 2014 | Tadze |
| Portugal | Autoridade Nacional do Medicamento (ANM) | 2014 | Tadze |
| Poland | Office for Registration of Medical Products (URPL) | 2014 | Tadze |
| Sweden | Läkemedelsverket | 2014 | Tadze |
| Netherlands | Nederlands Instituut voor Volksgezondheid en Milieu (RIVM) | 2014 | Tadze |
| Czech Republic, Hungary, Slovakia, Greece, Denmark, etc. | Corresponding national regulators | 2014–2015 | Tadze |
---
How the approval process unfolded
1. Patent landscape – The original tadalafil patents held by Eli Lilly expired in most EU member states around 2008–2009.
2. Generic development – Teva developed a high‑quality, bioequivalent formulation and filed a Marketing Authorization Application (MAA) with the EMA in early 2014.
3. EMA assessment – The European Commission, via the EMA’s Committee for Medicinal Products for Human Use (CHMP), reviewed the data and granted a central marketing authorization in July 2014 for the 5 mg, 10 mg, and 20 mg strengths.
4. National approvals – Once the central approval was issued, Teva received national authorisations in individual EU countries either simultaneously or within a few weeks.
5. Launch – Teva launched the product in 2015 under the brand name Tadze (in most markets) and also sells the same generic under its own “generic” label in some countries.
---
Current status
- Availability – The generic is sold in over 30 EU member states and in the UK (post‑Brexit approval).
- Branding – In most markets it is marketed as Tadze; in a few it appears simply as “generic tadalafil 5 mg” (e.g., in Spain, France, Germany).
- Pricing – Because it is a generic, prices are typically 30–50 % lower than the brand name Cialis.
- Patents – There are still some patent and design‑rights disputes in certain countries, but these have largely been settled or are pending in a few jurisdictions.
---
Quick Takeaway
Teva’s generic tadalafil (Tadze) is fully approved in the European Union, having received a central EMA authorization in 2014 and launched in 2015. It is available across most EU countries and the UK under the same generic formulation and dosage strengths (5 mg, 10 mg, 20 mg).